IOL Chemicals Q1 FY27 Earnings Call Transcript Released; Revenue Up 37%
IOL Chemicals reported Q1 FY27 revenue of ₹756 crore, up 37% YoY. EBITDA grew 60.7% to ₹111 crore, and PAT increased by 89.9% to ₹64.5 crore. Non-ibuprofen products drove pharma growth, contributing 43% of revenue. The company expects 15-20% revenue growth and 14-15% EBITDA margins for FY27.
The substantial year-on-year growth in key financial metrics, coupled with positive future guidance and strategic progress in product diversification, is likely to have a significant positive impact on investor sentiment and the company's stock performance.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, along with improved margins. The diversification into non-ibuprofen products and increased export contribution are positive indicators for future growth.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) has released the transcript of its Earnings Conference Call held on August 13, 2026, following the declaration of financial results for the first quarter of FY27, ending June 30, 2026.
During Q1 FY27, the company reported a revenue of ₹756 crore, marking a significant year-on-year growth of 37% compared to ₹551 crore in Q1 FY26. EBITDA stood at ₹111 crore, an increase of 60.7% from ₹69.5 crore in the same quarter last year, with EBITDA margins improving to 14.6% from 12.4%. Profit After Tax (PAT) grew by 89.9% to ₹64.5 crore from ₹34 crore in Q1 FY26, and PAT margins improved to 8.4% from 6.1%.
The company highlighted strong performance driven by healthy demand across key products, improved capacity utilization, a favorable product mix, and operational efficiencies. The pharmaceutical division saw non-ibuprofen products contributing 43% of revenue in Q1 FY27, up from 36% in Q1 FY26, with a 67% year-on-year revenue growth. Exports increased to 28.5% of revenue. The chemical business also performed well, supported by improved realizations and operational efficiencies.
Looking ahead, IOLCP remains confident in delivering 15% to 20% revenue growth for FY27, with an EBITDA margin in the range of 14% to 15%, and exports contributing approximately 25% to 30% of revenue. The company also anticipates revenue growth of 15% to 20% and EBITDA margins of 15% to 17% in FY28. The company is investing approximately ₹200 crore annually in capex, with 60% directed towards expansion and new products.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.